Sales

The latest news from the healthcare marketing and communications sector involving pharmaceutical, biotech and medical device companies.

Analysts: Merck’s Gardasil undervalued by billions of dollars
Analysts: Merck’s Gardasil undervalued by billions of dollars
Alison Kanski
December 7, 2018
10:51 am

Wolfe Research analysts say the market is underestimating the vaccine’s potential by more than $2 billion.

5 Steps to Successful Key Account Management
5 Steps to Successful Key Account Management
Chris Lundgren
February 27, 2015
4:30 pm

The healthcare ecosystem is changing rapidly to succeed requires the adoption of key account management (KAM), a systematic, robust alternative to the traditional buyer/seller model.

GlaxoSmithKline faces more Avandia fallout
GlaxoSmithKline faces more Avandia fallout
Marc Iskowitz
June 5, 2007
4:00 am

GlaxoSmithKline is in Congressional crosshairs over its marketing of Avandia, and investors arent happy either.

AMA hooks up online with Sermo
AMA hooks up online with Sermo
Matthew Arnold
June 5, 2007
4:00 am

The American Medical Association announced it is partnering with Sermo, the online community for physicians.

LLNS rebrands as LyonHeart
LLNS rebrands as LyonHeart
Stephen McGuire
June 5, 2007
4:00 am

Lyons Lavey Nickel Swift is rebranding as “LyonHeart” under its proprietary creative-strategic process dubbed “Disruption.”

Nexavar also seen as liver cancer breakthrough
Nexavar also seen as liver cancer breakthrough
Stephen McGuire
June 4, 2007
4:00 am

Onyx and Bayers kidney cancer drug Nexavar (sorafenib) was also found to extend the lives of liver cancer patients in a clinical trial by almost three months, or 44%, doctors said.

InVentiv buys brand ID shop Addison Whitney
InVentiv buys brand ID shop Addison Whitney
Matthew Arnold
May 31, 2007
4:00 am

InVentiv Health has acquired brand identity shop Addison Whitney.

Panel to review Sanofi-Aventis’ Ketek
Panel to review Sanofi-Aventis’ Ketek
November 15, 2006
8:32 pm

The FDA will convene a joint panel of outside experts to examine the risks and benefits of Sanofi-Aventis’ antibiotic Ketek (telithromycin).

Panel to review Sanofi-Aventis’ Ketek
Panel to review Sanofi-Aventis’ Ketek
November 15, 2006
8:32 pm

The FDA will convene a joint panel of outside experts to examine the risks and benefits of Sanofi-Aventis’ antibiotic Ketek (telithromycin).

AHA forbids Pfizer from presenting torcetrapib results
AHA forbids Pfizer from presenting torcetrapib results
November 15, 2006
12:15 am

Pfizer won’t be allowed to present new data on its closely watched developmental drug torcetrapib at the annual American Heart Association (AHA) meeting this week.

  • From Our Partners